Images (1)

Cisplatin

Authors:Prof. Dr. med. Peter Altmeyer, Prof. Dr. med. Martina Bacharach-Buhles

All authors of this article

Last updated on: 22.04.2021

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Platinum derivative with an alkylating effect on the DNA of tumour cells ( alkylans) for use as a cytostatic drug.

Half-lifeThis section has been translated automatically.

40-190 h (metabolites).

IndicationThis section has been translated automatically.

bronchial carcinomas, testicular tumours, ovarian and cervical carcinomas, malignant melanoma, sarcoma, spinocellular carcinoma.

Dosage and method of useThis section has been translated automatically.

Depending on the chemotherapy protocol (VBD, DVP, DPC, DPCTII) or 20-40 mg/m2 KO i.v. over 5 days every 3-4 weeks or 120 mg/m2 KO once every 3-4 weeks.

Notice! In patients of sexually mature age effective contraceptive measures must be taken during therapy and up to 3 months after therapy!

Undesirable effectsThis section has been translated automatically.

Cutaneous adverse reactions (most common): alopecia, pruritus, rush, stomatitis, dermatitis, allergic reactions up to anaphylactic reactions or Stevens-Johnson syndrome, Raynaud's symptoms, systemic scleroderma, skin necrosis after intra-arterial application.

Extracutaneous adverse reactions: haematopoietic disorders, gastrointestinal disorders, liver damage, kidney damage, cardiac arrhythmias, neurological disorders, visual, hearing and taste disorders, disorders of spermatogenesis and ovulation.

InteractionsThis section has been translated automatically.

Myelosuppressants increase the toxicity of cytostatic drugs, the NW of oto- and nephrotoxic drugs are increased, complexing agents reduce the effect of cisplatin.

ContraindicationThis section has been translated automatically.

Pregnancy, lactation, acute infections, severe bone marrow depression, exsiccosis, hypersensitivity to platinum-containing substances, renal insufficiency (nephrotoxic!).

PreparationsThis section has been translated automatically.

Cisplatin, Platiblastin, Platinex

Note(s)This section has been translated automatically.

To avoid kidney damage: infuse 1-2 litres of fluid 8-12 hours before chemotherapy or run the infusion for 24 hours!

LiteratureThis section has been translated automatically.

  1. Adoue D et alo. (1985) Raynaud's phenomenon after chemotherapy. Speaking of 3 cases. Ann Dermatol Venereol 112: 151-155
  2. Emir S et al (2001) Scleroderma in a child after chemotherapy for cancer. Clin Exp Rheumatol 19: 221-223
  3. Urba SG et al (2003) Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 98: 2177-2183
  4. Wenig BL et al (2002) The role of intratumoral therapy with cisplatin/epinephrine injectable gel in the management of advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 128: 880-885

Authors

Last updated on: 22.04.2021

Authors: Prof. Dr. med. Peter AltmeyerProf. Dr. med. Martina Bacharach-Buhles